AU2014203942B2 - Delayed-release composition comprising biguanide - Google Patents

Delayed-release composition comprising biguanide Download PDF

Info

Publication number
AU2014203942B2
AU2014203942B2 AU2014203942A AU2014203942A AU2014203942B2 AU 2014203942 B2 AU2014203942 B2 AU 2014203942B2 AU 2014203942 A AU2014203942 A AU 2014203942A AU 2014203942 A AU2014203942 A AU 2014203942A AU 2014203942 B2 AU2014203942 B2 AU 2014203942B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
composition according
metformin
minutes
biguanide compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014203942A
Other languages
English (en)
Other versions
AU2014203942A1 (en
Inventor
Alain D. Baron
Stephen Kwaku DORDUNOO
Mark S. Fineman
Terri KIM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anji Pharmaceuticals Inc
Original Assignee
Anji Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014203942(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anji Pharmaceuticals Inc filed Critical Anji Pharmaceuticals Inc
Publication of AU2014203942A1 publication Critical patent/AU2014203942A1/en
Application granted granted Critical
Publication of AU2014203942B2 publication Critical patent/AU2014203942B2/en
Assigned to ANJI PHARMA (US) LLC reassignment ANJI PHARMA (US) LLC Request for Assignment Assignors: ELCELYX THERAPEUTICS, INC.
Assigned to ANJI PHARMACEUTICALS INC. reassignment ANJI PHARMACEUTICALS INC. Request for Assignment Assignors: ANJI PHARMA (US) LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014203942A 2013-01-05 2014-01-03 Delayed-release composition comprising biguanide Active AU2014203942B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361749307P 2013-01-05 2013-01-05
US61/749,307 2013-01-05
PCT/US2014/010240 WO2014107617A1 (en) 2013-01-05 2014-01-03 Delayed-release composition comprising biguanide

Publications (2)

Publication Number Publication Date
AU2014203942A1 AU2014203942A1 (en) 2015-07-16
AU2014203942B2 true AU2014203942B2 (en) 2019-01-03

Family

ID=50030486

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014203942A Active AU2014203942B2 (en) 2013-01-05 2014-01-03 Delayed-release composition comprising biguanide

Country Status (19)

Country Link
US (3) US20140193498A1 (cg-RX-API-DMAC7.html)
EP (2) EP2941245B1 (cg-RX-API-DMAC7.html)
JP (1) JP6333855B2 (cg-RX-API-DMAC7.html)
KR (1) KR102229492B1 (cg-RX-API-DMAC7.html)
CN (2) CN110051638B (cg-RX-API-DMAC7.html)
AR (1) AR094374A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014203942B2 (cg-RX-API-DMAC7.html)
CA (1) CA2896864C (cg-RX-API-DMAC7.html)
CL (1) CL2015001914A1 (cg-RX-API-DMAC7.html)
CU (1) CU20150071A7 (cg-RX-API-DMAC7.html)
EA (1) EA039530B1 (cg-RX-API-DMAC7.html)
HK (1) HK1214966A1 (cg-RX-API-DMAC7.html)
IL (1) IL239722B (cg-RX-API-DMAC7.html)
MX (2) MX376822B (cg-RX-API-DMAC7.html)
NZ (1) NZ709525A (cg-RX-API-DMAC7.html)
PH (1) PH12015501520A1 (cg-RX-API-DMAC7.html)
SG (2) SG11201505240QA (cg-RX-API-DMAC7.html)
WO (1) WO2014107617A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201504858B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20201731T1 (hr) 2011-01-07 2020-12-25 Anji Pharma (Us) Llc Terapije na bazi liganda kemozensoričkog receptora
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
AU2013207329B2 (en) 2012-01-06 2017-10-26 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
KR20230095124A (ko) 2012-01-06 2023-06-28 앤지 파마 유에스 엘엘씨 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
PL3236943T3 (pl) * 2014-12-24 2023-05-29 Principia Biopharma Inc. Kompozycje do krętniczo-czczego dostarczania leków
WO2016205754A1 (en) * 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
WO2018132768A1 (en) * 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
FR3068601B1 (fr) * 2017-07-05 2021-02-19 Eric Joseph Marie Fulgence Janin Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire
EP3976022A4 (en) * 2019-06-03 2023-06-14 R.P. Scherer Technologies, LLC DELAYED RELEASE SOFT CAPSULES
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
US20230000820A1 (en) * 2021-06-28 2023-01-05 ImmunoMet Therapeutics, Inc. Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereof
CN119499203A (zh) 2023-08-22 2025-02-25 雅研(天津)生物医药科技中心(有限合伙) 一种盐酸二甲双胍肠溶片
CN119499228A (zh) 2023-08-22 2025-02-25 雅研(天津)生物医药科技中心(有限合伙) 盐酸二甲双胍肠溶制剂
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
WO2013103919A2 (en) * 2012-01-06 2013-07-11 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1209253A (en) 1913-01-09 1916-12-19 Automatic Electric Co Impulse-transmitting device.
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS58403B2 (ja) 1975-07-24 1983-01-06 武田薬品工業株式会社 Ｌ− アスコルビンサンセイザイノ セイゾウホウ
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
FR2704146B1 (fr) 1993-04-19 1995-07-13 Cripdom Microcapsules d'acide acétylsalicylique à libération contrôlée.
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
IL158466A0 (en) 1997-04-15 2004-05-12 Csir Pharmaceutical compositions having appetite suppressant activity
US5891919A (en) 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
IL132313A0 (en) 1999-10-11 2001-03-19 Yeda Res & Dev Leptin assay
US20110217394A1 (en) 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
EP1349531A1 (en) * 2001-01-12 2003-10-08 Sun Pharmaceuticals Industries Ltd. Spaced drug delivery system
WO2002078617A2 (en) 2001-03-28 2002-10-10 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
US8030008B2 (en) 2001-04-05 2011-10-04 Senomyx, Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
US20060019346A1 (en) 2002-07-29 2006-01-26 Senomyx, Inc. Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands
US7214387B2 (en) * 2002-08-02 2007-05-08 Penwest Pharmaceuticals Company Sustained release formulations of metformin
CN1413582A (zh) * 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 盐酸二甲双胍肠溶片及其制备方法
AU2003286069A1 (en) 2002-12-18 2004-07-09 Givaudan Sa Chimeric alpha q-gustducin g-proteins
DE10308504A1 (de) 2003-02-26 2004-09-09 Basf Ag Enzymatische Herstellung von (Meth)acrylsäureestern
US20060172020A1 (en) 2003-07-17 2006-08-03 Djang Arthur H Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabeties
KR20070053659A (ko) 2004-04-20 2007-05-25 도이체스 인스티튜트 퓌어 에른에룬그스포슝 쓴맛 수용체의 작용제 및 그의 용도
US20060024335A1 (en) 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
US7829299B2 (en) 2004-11-18 2010-11-09 Deutsches Institut fur Ernahrungforschung Potsdam-Rehbrucke Stiftung des Offentlichen Rechts Agonists of bitter taste receptors and uses thereof
CN101166742B (zh) 2005-04-28 2011-07-13 味之素株式会社 新型内酰胺化合物
US20060269617A1 (en) 2005-05-26 2006-11-30 Suracell, Inc. Supplement compositions and method of use for enhancement of insulin sensitivity
US7939276B2 (en) 2005-06-22 2011-05-10 Senomyx, Inc. Assays which screen for compounds that modulate bitter taste of chlorogenic lactone compounds
AU2006290352B2 (en) * 2005-08-30 2012-06-07 Abbott Healthcare Private Limited Extended release pharmaceutical composition of metformin and a process for producing it
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US20070104805A1 (en) 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
JP2007215162A (ja) 2006-01-11 2007-08-23 Canon Inc 情報処理装置及びその制御方法、プログラム、記憶媒体
US20070207227A1 (en) 2006-02-23 2007-09-06 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Appetite suppressant compositions
WO2007116404A2 (en) 2006-04-10 2007-10-18 Bar-Ilan University Cucurbitacin glucosides and use thereof in treating cancer
CA2551706A1 (en) 2006-06-27 2007-12-27 Innovative Life Sciences Corporation Herbal product comprising cinnamon and bitter melon
CN100596277C (zh) 2006-07-10 2010-03-31 博仲盛景医药技术（北京）有限公司 一种促进肠胃蠕动的药物组合物
WO2008019920A1 (en) 2006-08-17 2008-02-21 Unilever N.V. Processes for production of hoodia plant extracts containing steroidal glycosides
EP2054071A1 (en) 2006-08-24 2009-05-06 Unilever N.V. Process for preparing a composition comprising steroidal glycosides
US7811788B2 (en) 2006-09-05 2010-10-12 Senomyx Inc. Nucleic acid encoding a haplotype of human T2R receptor hT2R50
EP1975612A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
EP1975611A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
US20090042813A1 (en) 2007-08-10 2009-02-12 Sergey Michailovich Melnikov Hoodia extract oil compositions comprising medium chain triglycerides
US20100316736A1 (en) 2007-10-24 2010-12-16 Desert Labs Agriculture Cooperative Association Ltd. Appetite suppressant
EP2236149B1 (en) 2008-01-29 2014-06-18 Nakamori Pharmaceutical Co., Ltd. Medicinal composition for treating respiratory infectious diseases
WO2009140784A1 (en) 2008-05-23 2009-11-26 Givaudan Sa Bitter alkaloid containing consumables comprising bitter blockers
US8546085B2 (en) 2008-06-13 2013-10-01 Givaudan Sa Methods of identifying modulators of the bitter taste receptor TAS2R44
US8557530B2 (en) 2008-08-29 2013-10-15 Givaudan Sa Use of a TAS2R7 nucleic acid sequence to identify modulators
TWI469779B (zh) 2008-08-29 2015-01-21 Suntory Holdings Ltd Novel epigallocatechin gallate 4, and its vascular endothelial function enhancer
WO2010060198A1 (en) 2008-11-26 2010-06-03 West Central Envirotech Inc. Composition and method for controlling insects
EP2385049A4 (en) 2009-01-03 2012-08-08 Shizuoka Prefecture Public University Corp SULFATED C-GLYCOSIDE, METHOD FOR THE ISOLATION THEREOF AND METHOD FOR THE SYNTHESIS THEREOF
WO2011012298A1 (en) 2009-07-28 2011-02-03 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Agonists and antagonists of human bitter taste receptor tas2r49 and uses thereof
CA2777938C (en) 2009-10-21 2017-11-14 Wisconsin Alumni Research Foundation Method of preventing type 1 diabetes
WO2011068814A1 (en) 2009-12-04 2011-06-09 Colgate-Palmolive Company Oral compositions containing extracts of garcinia mangostana l. and related methods
EP2345646A1 (en) 2010-01-14 2011-07-20 InterMed Discovery GmbH Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
US20110293753A1 (en) 2010-05-28 2011-12-01 Louis Bellafiore Tocotrienol Compositions
GB201009873D0 (en) 2010-06-14 2010-07-21 Univ Leuven Kath Method for hydrogenation of isoalpha-acids (isohumulones) to hexahydro-iso-alpha-acids (hexahydro-isohumulones) by using heterogeneous ruthenium
EP2397039A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Compositions for delaying progression of diabetes using Salacia oblonga extract
CN101978956B (zh) * 2010-10-13 2012-03-28 北京京丰制药有限公司 盐酸二甲双胍肠溶片及其制备方法
HRP20201731T1 (hr) * 2011-01-07 2020-12-25 Anji Pharma (Us) Llc Terapije na bazi liganda kemozensoričkog receptora
CN103768071B (zh) * 2012-10-23 2016-08-17 中国医药工业研究总院 一种治疗糖尿病的口服制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
WO2013103919A2 (en) * 2012-01-06 2013-07-11 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders

Also Published As

Publication number Publication date
US20250000804A1 (en) 2025-01-02
PH12015501520A1 (en) 2015-09-21
MX389344B (es) 2025-03-20
SG11201505240QA (en) 2015-08-28
CN110051638B (zh) 2022-02-01
EA039530B1 (ru) 2022-02-08
EP2941245B1 (en) 2024-06-26
ZA201504858B (en) 2018-12-19
CN105101956B (zh) 2018-12-07
IL239722B (en) 2022-04-01
MX2020011594A (es) 2022-01-13
EP2941245A1 (en) 2015-11-11
JP6333855B2 (ja) 2018-05-30
CN105101956A (zh) 2015-11-25
US20200093750A1 (en) 2020-03-26
WO2014107617A1 (en) 2014-07-10
CA2896864A1 (en) 2014-07-10
CN110051638A (zh) 2019-07-26
US20140193498A1 (en) 2014-07-10
MX2015008625A (es) 2015-09-23
AU2014203942A1 (en) 2015-07-16
IL239722A0 (en) 2015-08-31
EA201591085A1 (ru) 2015-12-30
MX376822B (es) 2025-03-07
NZ709525A (en) 2020-07-31
KR102229492B1 (ko) 2021-03-17
KR20150103079A (ko) 2015-09-09
BR112015016111A2 (pt) 2020-01-28
AR094374A1 (es) 2015-07-29
JP2016504384A (ja) 2016-02-12
HK1214966A1 (zh) 2016-08-12
CL2015001914A1 (es) 2015-09-04
SG10201705437SA (en) 2017-07-28
EP4410380A2 (en) 2024-08-07
CA2896864C (en) 2021-04-20
CU20150071A7 (es) 2016-01-29
EP4410380A3 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
US20250000804A1 (en) Compositions and methods for treating metabolic disorders
US10603291B2 (en) Compositions and methods for treating metabolic disorders
US10201511B2 (en) Compositions and methods for treating metabolic disorders
JP7403259B2 (ja) 代謝障害を治療するための組成物および方法
US10159658B2 (en) Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2872127A1 (en) Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11974971B2 (en) Compositions and methods for treating metabolic disorders
HK40012109A (en) Delayed-release composition comprising biguanide
HK40012109B (zh) 包含双胍的延迟释放组合物
HK40021394A (en) Compositions and methods for treating metabolic disorders
BR112015016111B1 (pt) Composição farmacêutica de liberação retardada para entrega de composto de biguanida e uso de um composto de biguanida ou sal do mesmo

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ANJI PHARMA (US) LLC

Free format text: FORMER OWNER(S): ELCELYX THERAPEUTICS, INC.

PC Assignment registered

Owner name: ANJI PHARMACEUTICALS INC.

Free format text: FORMER OWNER(S): ANJI PHARMA (US) LLC